CV Sciences, Inc. Sells $13.6 Million Worth of CBD Products in Q3 | CashCropToday
0 Shares 105 Views

CV Sciences, Inc. Sells $13.6 Million Worth of CBD Products in Q3

November 7, 2018
105 Views

CV Sciences, Inc. (OTCQB:CVSI) has announced this morning the company’s Q3 financials for 2018. Their hemp derived Cannbidiol (CBD) product brand +CBD Oil is one of the most popular in the United States. Their brand sells capsules, tinctures, sprays, topicals, gummy’s, and CBD oil in bulk from their website as well as in a number of retail stores.

Financial Highlights for Q3:

  • Record Sales of $13,600,000, an increase of 143% compared to Q3 2017
  • Record Gross Profit of $9,945,000, an increase of 149% compared to Q3 2017
  • Record GAAP Net Income of $3,295,000, an improvement of $3,885,000 compared to Q3 2017
  • Record Adjusted EBITDA of $4,128,000, an improvement of $3,253,000 compared to Q3 2017

First Nine Months of 2018 Financial Highlights

  • Record Sales of $34,020,000, an increase of 153% compared to the first nine months of 2017
  • Record Gross Profit of $24,567,000, an increase of 165% compared to the first nine months of 2017
  • GAAP Net Income of $7,100,000, an improvement of $12,467,000 compared to the first nine months of 2017
  • Record Adjusted EBITDA of $9,796,000, an improvement of $10,267,000 compared to the first nine months of 2017
  • Cash Flow from Operations of $9,926,000, with a cash balance increase of $3,800,000 during Q3 2018

Joseph Dowling, Chief Executive Officer of CV Sciences, gave this statement in the press release, “We are encouraged by our performance as we delivered another strong quarter, including our third consecutive quarter of profitability. This was led by initiatives that include accelerating our brand recognition and brand loyalty and growing sales distribution channels that have generated triple-digit year-over-year revenue growth and double-digit sales growth on a sequential quarterly comparison.”

You may be interested

Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio Oregon
Market Watch
274 views
Market Watch
274 views

Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio Oregon

Editor - November 27, 2018

Vancouver, BC -- (November 27, 2018) -- GLOBAL HEMP GROUP INC. (“GHG” or the “Company”) (CSE: GHG / OTC: GBHPF / FRANKFURT: GHG) and its joint venture…

Wayland Group Enters UK Cannabis Market with Theros Pharma Acquisition
Global
195 views
Global
195 views

Wayland Group Enters UK Cannabis Market with Theros Pharma Acquisition

Editor - November 26, 2018

Wayland Group (CSE:WAYL) (OTCQB:MRRCF) has announced this morning that their company has entered into an agreement to acquire 51% of UK company Theros Pharma Ltd. The Wayland Group…

GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical Trials
Manufacturing
191 views
Manufacturing
191 views

GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical Trials

Editor - November 26, 2018

GW Pharmaceuticals (Nasdaq: GWPH) has announced this morning that their company has completed a double-blind, placebo-controlled Phase 3 clinical trial for its Cannabidiol (CBD) derived product EPIDIOLEX®.…

Leave a Comment

Your email address will not be published.

Most from this category

%d bloggers like this: